> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Advises Phase 3 Trial for ERC-USA’s ERC Glioblastoma Vaccine
- URL: https://www.fdaweb.com/fda-advises-phase-3-trial-for-erc-usas-erc-glioblastoma-vaccine/
- Published: 2021-04-07T12:00:00.000Z
- Updated: 2026-09-14T16:53:57.000Z
- Author: David McFarland
- Tags: Biologics, Drugs, #legacy-id-D5149060

FDA has recommended an early termination for a ERC-USA and University of California, Irvine, Phase 2 trial of ERC 1671 (Gliovac or Sitoiganap) for treating glioblastoma and recommended that the parties pursue a confirmatory Phase 3 registration trial to support a BLA application. ERC-USA [says](https://www.globenewswire.com/news-release/2021/04/07/2205843/0/en/ERC-USA-Announces-FDA-Recommendation-for-Early-Termination-of-Phase-2-Clinical-Trial-of-ERC1671-Gliovac-or-Sitoiganap-and-Application-for-Registration-Trial-for-Treatment-of-Gliobl.html?ref=fdaweb.com) the agency advice is “a major advance for the clinical development of ERC 1671, a cell-based immunotherapy currently under development for the treatment of recurrent glioblastoma for which there are no effective available treatments.”